Acute Myelogenous Leukemia Stem Cell Treatments
Understanding AML and Its Impact
Acute Myelogenous Leukemia (AML) is an aggressive form of blood cancer that begins in the bone marrow, where blood cell production occurs. It causes the rapid growth of abnormal white blood cells, which interfere with the production of healthy red blood cells and platelets.
Traditional AML treatments, such as chemotherapy and radiation, aim to eliminate cancerous cells but can severely affect healthy tissues. At 1 STEM CELL, our approach focuses on regenerative support using stem cell therapy, designed to help restore bone marrow function and support immune system recovery following conventional treatments.
The use of mesenchymal stem cells (MSCs) has shown potential to reduce inflammation, support hematopoietic (blood-forming) recovery, and improve patient outcomes when used in conjunction with standard oncological care. This therapy does not replace traditional cancer treatments, but it may serve as a complementary option to help enhance healing and reduce complications from intensive therapies.
Stem Cell Support for AML Recovery
Stem cell therapy in AML recovery aims to rebuild healthy bone marrow and regulate immune responses that have been damaged by chemotherapy or radiation. By promoting cellular repair, MSCs help reduce fatigue, improve recovery time, and support overall vitality.
All treatments at 1 STEM CELL use ethically sourced, umbilical cord-derived stem cells processed under strict medical standards. Our specialized protocols are developed to assist the patient’s body in regenerating healthier cells and regaining balance after aggressive therapy.
Each case is reviewed individually by our medical team to ensure treatment suitability, always prioritizing patient safety, clinical evidence, and quality of life improvement.